Michael H. Davidson to Disease Progression
This is a "connection" page, showing publications Michael H. Davidson has written about Disease Progression.
Connection Strength
0.483
-
Changing characteristics of statin-related cIMT trials from 1988 to 2006. Atherosclerosis. 2016 Mar; 246:121-9.
Score: 0.098
-
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
Score: 0.078
-
The role of cardiologists in the management of patients with diabetes is evolving owing to the close relationship between diabetes and CAD. Introduction. Am J Cardiol. 2011 Aug 02; 108(3 Suppl):1B-2B.
Score: 0.073
-
Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study. Arterioscler Thromb Vasc Biol. 2010 Sep; 30(9):1873-6.
Score: 0.067
-
Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation. 2008 Apr 22; 117(16):2123-30.
Score: 0.058
-
Developmental Trajectories of Impaired Community Functioning in Schizophrenia. JAMA Psychiatry. 2016 Jan; 73(1):48-55.
Score: 0.025
-
Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women. Vasc Health Risk Manag. 2012; 8:31-8.
Score: 0.019
-
Peripheral artery disease, biomarkers, and darapladib. Am Heart J. 2011 May; 161(5):972-8.
Score: 0.018
-
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA. 2009 Mar 18; 301(11):1131-9.
Score: 0.015
-
Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006 Mar 23; 354(12):1253-63.
Score: 0.013
-
Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation. 2002 Feb 26; 105(8):917-22.
Score: 0.009
-
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. Am Heart J. 2001 May; 141(5):722-6.
Score: 0.009